INO-3112

BIOLOGICAL2 trials

Sponsors

Inovio Pharmaceuticals

Conditions

Cervical CancerHead and Neck Squamous Cell Cancer

Phase 1

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

CompletedNCT02163057

Inovio PharmaceuticalsHead and Neck Squamous Cell Cancer

Start: 2014-08-13End: 2017-01-23Updated: 2021-01-22

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

CompletedNCT02172911

Inovio PharmaceuticalsCervical Cancer

Start: 2014-06-06End: 2017-09-07Updated: 2021-02-21

Related Papers

A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer.

Journal of Clinical Oncology2018-05-204 citations

Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).

Journal of Clinical Oncology2017-05-208 citations